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Abstract 
 
Background 
Asenapine is a new second generation antipsychotic, that is understudied in borderline 
personality disorder (BPD). Only one study investigating the use of the drug in this indication (an 
open-label pilot study) has been conducted to date. 
Objective 
The present open label randomised controlled trial aimed to evaluate the efficacy and tolerability 
of asenapine in comparison with olanzapine, the most broadly studied antispychotic in BPD. 
Methods 
51 outpatients aged between 18 and 50 years, with a diagnosis of BPD based on DSM-5 criteria 
were assigned for 12 weeks to: (1) asenapine (5-10 mg/day) or (2) olanzapine (5-10 mg/day).  
Participants were assessed at baseline and after 12 weeks with: Clinical Global Impression Scale, 
Severity item (CGI-S), Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating 
Scale (HAM-A), Social Occupational Functioning Assessment Scale (SOFAS), Borderline 
Personality Disorder Severity Index (BPDSI), Barratt Impulsiveness Scale, version 11 (BIS-11), 
Modified Overt Aggression Scale (MOAS), Self Harm Inventory (SHI), and Dosage Record and 
Treatment Emergent Symptom Scale (DOTES). 
Analysis of variance repeated measures was performed. Intention to treat analysis with last 
observation carried forward was conducted. 
Results 
Drop-outs were 11 (21.57%): six patients taking asenapine and five patients receiving olanzapine. 
Two patients who received asenapine stopped the drug, one due to oral hypoesthesia and the 
other due to  moderate anxiety. Two patients receiving olanzapine discontinued the treatment for 
a significant weight gain ( ≥ 3 Kg).  The remaining seven drop-outs resulted from the lack of 
compliance with the trial prescription.  Forty out of the 51 patients (78%) completed the trial: 19 
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patients received asenapine, while 21 patients received olanzapine.We found a significant within- 
subjects effect (trial duration) for all rating scales, except from the HAM-D, the MOAS, and two 
items of the BPDSI: namely, “identity disturbance” and “parasuicidal behaviors”. A significant 
effect between subjects was found for the two items of the BPDSI: “affective instability” and 
“dissociation/paranoid ideation”. Asenapine was found superior to olanzapine in reducing the 
affective instability score (P = 0.001), whereas olanzapine was found superior to asenapine in 
reducing dissociation/paranoid ideation (P = 0.012). However, the study was found to be 
underpowered to detect a difference between the drugs on the dissociation/paranoid ideation item 
of the BPDSI. Two patients receiving asenapine experienced akathisia and another two 
restlessness/anxiety, while three patients receiving olanzapine reported somnolence and two 
fatigue. 
Conclusions 
Asenapine and olanzapine were demonstrated to have a similar efficacy.  While asenapine was 
found to be more efficacious than olanzapine in treating affective instability, olanzapine was 
superior to asenapine in treating paranoid ideation and dissociation. However, the study was 
underpowered to detect a difference between groups on the dissociation/paranoid ideation item. 
Both medications were well tolerated, with asenapine being related to a higher frequency of oral 
hypoaestesia and akathisia, and olanzapine being prone to induce weight gain. 
The open label study design, lack of a placebo group, and small sample size constituted major 
limitations of this trial. Our findings require to be replicated in further studies. 
The trial was registered in the Australian New Zealand Clinical Trials Registry (code: 
ACTRN12614000551695). 
 
Key points: The new antipsychotic asenapine had the same global efficacy as olanzapine in 
treating borderline personality disorder. It had better results on affective instability, while 
olanzapine was more effective on cognitive-perceptual symptoms. However, the study was found 
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to be underpowered to detect a difference between the drugs on the dissociation/paranoid ideation 
item. 
Adverse effects were mild but different between drugs, with oral dysesthesia more common with 
asenapine and weight gain more common with olanzapine. 
These results are useful to guide clinicians’choice of treatment for BPD. 
 
1. Introduction 
Treatment of borderline personality disorder (BPD) is very complex, mainly due to the 
heterogeneity of clinical manifestations and poor adherence of patients to therapeutic 
interventions. Although many drugs were investigated across studies generating promising 
findings, firm conclusions regarding efficacy cannot be drawn due to methodological limitations.  
Furthermore, clinicians are often faced with an even more challenging situation, as 
recommendations provided in treatment guidelines are somewhat discordant.  In particular, the 
UK National Institute for Health and Clinical Excellence [1] guidelines suggested 
psychotherapeutic interventions as the treatment of choice for BPD, thereby confining the 
pharmacological tools to a secondary role.  On the other hand, the American Psychiatric 
Association [2,3] put forward a treatment approach that is based on a symptom-oriented 
pharmacotherapy.   
In the last years, results of meta-analyses [4] and findings of systematic reviews [5,6] have 
induced a noticeable shift of experts’ opinions and clinical practice from the use of 
antidepressants to mood-stabilizers, omega-3 fatty acids, and second generation antipsychotics in 
the treatment of BPD.  Therapeutic effects of antipsychotic drugs were demonstrated across a 
wide range of symptoms.  Whilst their action is primarily directed at alleviating cognitive- 
perceptual symptoms such as transient paranoid ideation or dissociative symptoms, these agents 
were further reported to induce significant improvements across other psychopathological 
domains including mood instability, anxiety, impulsiveness, and aggression [7-9].  
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Among novel antipsychotics olanzapine is the most extensively studied across case-reports [10], 
open-label studies [11,12] and double-blind controlled trials (RCT) of patients with a diagnosis of 
BPD [13-21]. Antipsychotic drugs may owe their therapeutic efficacy to actions at D2-D4 and 
5HT-2A receptors, while adverse effects are believed to be induced by antagonist activity at H1, 
M1-M5, and α1 receptors [22].  
To date, ten RCTs have been conducted in samples with BPD to assess the efficacy of olanzapine 
versus placebo [13,16,23,19,21], versus active drugs [14,17,20], or versus placebo in a combined 
treatment with psychotherapy (dialectical behavioral therapy) [15,18].  The majority of 
accumulated evidence suggests that olanzapine is efficacious in treating cognitive-perceptual 
symptoms (psychotic-like symptoms), and in producing significant reduction in mood instability 
and impulsive behavioral dyscontrol.   
Asenapine is the most recent compound approved for the acute treatment of schizophrenia and 
mania associated to bipolar disorder.  This drug is available as a sublingual tablet formulation and 
acts as an antagonist at serotonin, dopamine, histamine and α-2 adrenergic receptors, with almost 
no binding affinity for muscarinic receptors [24].  A considerable number of randomized 
controlled trials were performed to test the efficacy of asenapine in comparison with placebo [25-
27] or active drugs [28,29] in schizophrenia.  Other studies evaluated the efficacy and tolerability 
of this drug in treating manic or mixed episodes of bipolar disorder, either in monotherapy or in 
adjunction to lithium or valproate [30-32].  Only one open-label study tested the efficacy of 
asenapine in 12 borderline personality disorder [33], and found that after 8 weeks of treatment 
with asenapine (5-20 mg/day) it was efficacious, not only against BPD general symptomatology, 
but more specifically affective instability, impulsivity, and cognitive symptoms. 
With regard to tolerability, novel antipsychotics present a more favorable tolerability profile over 
traditional neuroleptics.  Indeed, the former are associated with fewer and milder extrapyramidal 
adverse effects, a lower risk for developing tardive dyskinesia, as well as the possibility of 
enhancing cognitive functions [34].   
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Nevertheless, several adverse effects have been recorded for both olanzapine and asenapine, with 
some differences between the two drugs.  In particular, the most frequent side effects that may be 
caused by olanzapine are somnolence, fatigue, hyperprolactinaemia, increase in metabolic 
parameters (glucose, triglycerides, cholesterol) and a significant weight gain [35,18].  Although 
asenapine may also cause somnolence, glucose increase, and weight gain, recent systematic 
reviews of data from asenapine placebo- or olanzapine-controlled clinical trials showed that 
asenapine was less likely than olanzapine to induce weight gain and change the levels of glucose, 
triglycerides, and cholesterol [36-38,29].  Among adverse effects most frequently related to 
asenapine are anxiety, several extra-pyramidal symptoms, in particular akathisia, and 
dysgeusia/oral hypoesthesia [36].  
The present randomized controlled trial set out to compare the efficacy and tolerability of 
asenapine and olanzapine in the treatment of BPD patients, in order to elucidate the relevant 
efficacy and tolerability profile of asenapine across specific symptom clusters.  
 
2. Methods 
A sample of 51 consecutive outpatients, aged between 18 and 50 years, with a diagnosis of BPD 
based on DSM-5 criteria [39] were recruited in the study between June 2014 and February 2016.  
Patients attended the Centre for Personality Disorders of the Psychiatric Clinic, Department of 
Neuroscience, University of Turin, Italy. The psychiatric diagnosis was made by an expert 
clinician and confirmed with the Structured Clinical Interview for DSM-IV Axis I and II 
Disorders [40,41].  Exclusion criteria were: (1) a diagnosis of dementia or other cognitive 
disorders, schizophrenia or other psychotic disorders, or bipolar disorders, (2) a co-occurring 
major depressive episode and/or substance abuse, (3) and the administration of psychotropic 
medications and/or psychotherapy in the two months preceding the beginning of the study.  
Female patients who did not use an adequate birth control method were also excluded.  Each 
patient participated voluntarily in the study after providing written informed consent. The study 
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was conducted in compliance with the Declaration of Helsinki guidelines. Approval was obtained 
from the ethics committee of the University Hospital “Città della Salute e della Scienza – 
Ospedale dell’Ordine Mauriziano” of Turin. The trial was registered in the Australian New 
Zealand Clinical Trials Registry (ANZCTR), and allocated the following code: 
ACTRN12614000551695. 
Patients were randomly assigned to two arms of treatment for 12 weeks: (1) asenapine (dose 
range: 5-10 mg/day); (2) olanzapine (dose range: 5-10 mg/day). Research Randomizer (Urbaniak 
and Plous, Social Psychology Network Wesleyan University, Middletown, CT), a free web-based 
service for randomization, was used.  All drugs were titrated (for the first five days at the dose of 
5 mg/day and after at the dose of 10 mg/day, if the drug was well tolerated). We administered 
low doses of both drugs as suggested by the American Psychiatric Association guidelines (3). 
Concerning previous investigations, the only study of asenapine in BPD patients (33) used a 
broad dose range of 5-20 mg/day. As for olanzapine, several studies (12, 13, 17, 21) chose the 
same dose range of 5-10 mg/day used in our study. 
Patients were assessed at baseline and after 12 weeks with the following assessment instruments:  
1) the Clinical Global Impression Scale, Severity item (CGI-S) [42],  
2) the Hamilton Depression Rating Scale (HAM-D) [43], 
3) the Hamilton Anxiety Rating Scale (HAM-A) [44], 
4) the Social Occupational Functioning Assessment Scale (SOFAS) [45],  
5) the Borderline Personality Disorder Severity Index (BPDSI) [46],  
6) the Barratt Impulsiveness Scale, version 11 (BIS-11) [47],  
7) the Modified Overt Aggression Scale (MOAS) [48],  
8) the Self Harm Inventory (SHI) [49].  
Adverse effects of the two drugs were assessed with the Dosage Record and Treatment Emergent 
Symptom Scale (DOTES) [50].  
The CGI is a clinician-rated instrument to make global assessment of illness and it consists of 
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three different measures: severity of illness, global improvement, and efficacy index.  In this 
study severity of illness was considered and measured with the seven-point scale ranging from 1 
(normal) to 7 (extremely ill). 
The HAM-D is a clinician-rated scale that scores severity of 21 depressive symptoms in the last 
week.  Items are variably scored 0-2, 0-3, or 0-4, with a total score ranging from 0 to 64. The 
HAM-A is a clinician-rated scale scoring severity of 14 symptoms of anxiety in the last week.  
Item are all scored 0-4, with a total score ranging from 0 to 56.  
The SOFAS is a clinician-rated scale developed to measure a patient’s impairment in social and 
occupational domains. It is independent of the severity of patients’ symptoms. The scores  range 
between 0 to 100 with higher scores indicative of a better functioning. 
The BPDSI is a semi-structured clinical interview assessing frequency and severity of BPD 
related symptoms.  The interview consists of eight items scored on 10-point frequency scales 
(0=never; 10=daily), including ‘abandonment’, ‘interpersonal relationships’, ‘impulsivity’, 
‘parasuicidal behavior’, ‘affective instability’, ‘emptiness’, ‘outbursts of anger’, ‘dissociation and 
paranoid ideation’, and of one item scored on a 4-point severity scale, concerning ‘identity’.  
The BIS-11 is a 30-item self-report questionnaire used to measure the trait of impulsivity on a 4-
point Likert scale.  Higher scores for each item indicate higher levels of impulsivity. Twelve 
items are reverse-scored, in order to avoid response sets.  
The MOAS is a clinician-rated scale consisting of four subscales for different types of aggression 
(verbal aggression, aggression against objects, aggression against others, and self-aggression). 
The subscales are rated on a 5-point scale (score 0-4) [48].  
The SHI is a brief, self-report instrument which provides data on clinically relevant self-harm 
behaviors.  The scoring of the instrument is easily determined by counting the number of 
endorsed self-harm behaviors. 
The DOTES is a rating scale to measure the presence and intensity of side effects induced by 
psychotropic medications.  It consists of a broad range of 41 parameters including items on 
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posture and movement, alertness, and cardiovascular, oral, nasal, bowel, and dermatological 
problems. 
Assessment was performed by an investigator (P.B.) who had received a training session on 
psychometric instruments prior to the study.  
Statistical analysis were performed both in the group of patients who completed the trial and in 
the whole group of patients who were randomized including drop-outs.  In the second group, 
intention to treat (ITT) analysis was performed with the last observation carried forward (LOCF).  
Baseline mean scores of rating scales were compared between the two treatment groups with one-
way analysis of variance (ANOVA).  Comparison of score change at the end of the trial between 
the two groups was calculated for each rating scale with the analysis of variance (ANOVA) 
repeated measures. Bonferroni correction was applied to correct for multiple comparisons.  Effect 
size was calculated as eta square. 
Software system SPSS 22.0 (IBM Corporation, 2013) was used for calculations. P values were 
considered significant at ≤ 0.05. 
 
3. Results 
Fifty-one patients were randomly assigned to (1) asenapine (N=25) or to (2) olanzapine (N=26).  
Forty out of the 51 patients (78%) completed 12 weeks of the trial: 19 patients (47.5% of the 
completers) received asenapine, while 21 patients (52.5%) received olanzapine. Eleven patients 
(21.57%) discontinued the treatment at the fourth week: six taking asenapine and five receiving 
olanzapine.  The final sample resulted in 40 patients with the  mean age of 24.7 ± 5.3 years; they 
were 15 males (37.5%) and 25 females (62.5%). 
Results of the ANOVA calculated for baseline mean scores of rating scales are reported in Table 
1 and Table 2. No significant differences between groups were found at baseline between the two 
treatment arms. 
The ITT-LOCF analysis was performed on the entire sample of 51 patients recruited. Results of 
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the ANOVA repeated measures of the effects of trial duration (within-subjects effect) and 
treatment modality (between-subjects effect) on the score changes after 12 weeks are reported in 
Table 3, Table 5, and Table 7.  
We found a significant within- subjects effect (trial duration) for all rating scales (P ranged from 
0.001 to 0.012; ῃ2 ranged from 0.53 to 0.25), except from the HAM-D (P = 0.862; ῃ2 = 0.01), the 
MOAS (P = 0.119; ῃ2 = 0.1); and two items of the BPDSI: namely, “identity disturbance” (P = 
0.541; ῃ2  = 0.02) and “parasuicidal behaviors” (P = 0.092; ῃ2  = 0.14). Furthermore, a significant 
effect between subjects (treatment modality) was found for two items of the BPDSI: “affective 
instability” (P = 0.001, ῃ2 = 0.53), and “dissociation/paranoid ideation” (P = 0.021; ῃ2 = 0.21).  In 
particular, asenapine was found superior to olanzapine in reducing the affective instability score, 
whereas olanzapine was found superior to asenapine in reducing dissociation/paranoid ideation.  
We performed a post-hoc power calculation using the software tool ClinCalc.com (ClinCalc 
LLC, 2017). As the main objective of our study was to detect the differences between the drugs 
concerning specific symptom clusters, we applied the post-hoc power calculation to the two 
BPDSI items with a significant difference between groups: “affective instability” and 
“dissociation/paranoid ideation”. We obtained a power of 100% for “affective instability”, but 
only of 39% for “dissociation/paranoid ideation”. These results demonstrated that the study was 
underpowered to detect a difference between the drugs on the “dissociation/paranoid ideation” 
item of the BPDSI. 
Results of the analysis performed on the sample of 40 completers are reported in Table 4, Table 
6, and Table 8.  The significant effects found in the group of completers were not different from 
those found in the entire sample of 51 patients recruited.  In particular, a significant effect within 
subjects (trial duration) was confirmed for all rating scales (P ranged from 0.001 to 0.013; ῃ2 
ranged from 0.53 to 0.24) except from the HAM-D (P = 0.775; ῃ2 = 0.01), the MOAS (P = 0.119; 
ῃ2 = 0.1), and the two items of BPDSI: “identity disturbance” (P = 0.437; ῃ2 = 0.02) and 
“parasuicidal behaviors” (P = 0.086; ῃ2 = 0.14). The significant effect between subjects 
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(treatment modality) was confirmed for two items of BPDSI: “affective instability” (P = 0.001; 
ῃ2 = 0.53), and “dissociation/paranoid ideation” (P = 0.012; ῃ2 = 0.25). 
Out of the eleven subjects who discontinued treatment, five (three taking asenapine and two 
taking olanzapine) dropped-out due to adverse effects.  Specifically, two patients who received 
asenapine stopped the drug, one due to oral hypoesthesia and the other due to  moderate anxiety. 
Two patients receiving olanzapine discontinued the treatment after experiencing a significant 
weight gain ( ≥ 3 Kg).  The remaining seven drop-outs resulted from the lack of compliance with 
the trial prescription.  The overall side effects reported in the two arms of treatments were mild to 
moderate.  In the asenapine treatment arm two patients experienced akathisia and other two 
restlessness/anxiety, while in the olanzapine group somnolence was observed in three patients 
and fatigue in two.  
 
 
4. Discussion 
The present randomized controlled study tested the efficacy and tolerability of asenapine in 
comparison with olanzapine in patients affected by BPD.  The aim was to investigate whether the 
two drugs had different effects on specific symptom clusters and profiles of tolerability.   As no 
prior efficacy trials of asenapine versus olanzapine in BPD are  available in the literature, our 
findings are interpreted in the light of results from head to head comparisons of these two drugs 
in schizophrenia and in bipolar disorder, as well as studies testing the efficacy of asenapine and 
olanzapine separately in BPD samples.   
In our trial we found that the overall efficacy of asenapine was not different from olanzapine 
regarding global symptoms assessed with the CGI-S score, anxiety measured with the HAM-A 
score, and social and occupational functioning assessed with the SOFAS score.  Our finding of 
no difference in the efficacy of asenapine and olanzapine in improving global symptomatology is 
consistent with reports of meta-analysis [51] of data collected from patients with schizophrenia, 
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and with results from clinical trials [30] of patients affected by bipolar disorder.   More 
specifically, Szegedi and colleagues [51] concluded that in acute schizophrenia the reduction of 
global symptomatology, as measured with the Positive and Negative Symptoms Scale (PANSS), 
did not reach a statistically significant difference between treatments with asenapine and 
olanzapine.  Moreover, a double-blind trial of patients with bipolar disorder showed non-
inferiority of asenapine relative to olanzapine in extended treatment of bipolar patients during a 
manic episode [30]. 
Furthermore, we observed that, neither asenapine nor olanzapine led to significant decrease of 
depressive symptoms in our sample.  This result is substantially in accordance with preliminary 
evidence provided by Buchanan and colleagues [28], who found only a minimal effect of both 
asenapine and olanzapine on depressive symptoms in schizophrenic patients.  In addition, this 
lack of positive effect of asenapine on depressive symptoms in BPD has already been 
demonstrated in an open-label study published by Martin-Blanco and colleagues [33].  These 
trends are inconsistent with results of other two clinical trials of subjects with bipolar disorder 
[52], where asenapine was found superior to olanzapine in improving depressive symptoms 
during manic or mixed episodes.  A possible reason for this inconsistency may be that, whilst in 
our sample HAM-D scores at baseline were rather low (with a mean lower than 13) as patients 
with concomitant major depression had been excluded, in the other two studies of bipolar 
disorder patients [52] depressive symptoms were rated as “clinically relevant”.  
In our study we found that neither drug significantly improved aggressive symtpoms. This 
finding did not confirm previous data obtained by Amon and colleagues (53) in a group of 
inpatients with aggressiveness measured with the MOAS. In that study, the Authors showed a 
significant reduction of physical aggressiveness in the group that received asenapine versus usual 
management. The discrepancy with our results may be due to a number of factors. Baseline 
MOAS total score (Mean ± SD = 19 ± 9.80) in patients enrolled by Amon and colleagues was 
significantly higher than baseline MOAS score (Mean ± SD =  5.50 ± 2.59) registered in our 
13 
 
sample. Moreover, patients enrolled by Amon and colleagues (53) were not BPD patients but 
inpatients with schizophrenia and bipolar disorders. In the only previous investigation performed 
by Martin-Blanco and colleagues (33) with asenapine in BPD subjects the symptom of 
aggressiveness was not considered. So, we cannot compare with other investigations our finding 
of the lack of effect of asenapine on aggressive symptoms. Concerning the effects of olanzapine 
on aggression in BPD there is not an overall agreement among the Authors who conducted 
previous studies. Cochrane systematic reviews on pharmacological treatment for BPD (5,6) 
concluded that olanzapine induced significant decreases in affective instability, anxiety, anger, 
and psychotic paranoid symptoms. Aggressiveness was not listed among these effects. 
With regard to the role of asenapine and olanzapine in treating specific BPD symptoms, we found 
that the two antipsychotics produced non-different effects on BPD related psychopathology, 
impulsivity, and self-injury, measured with the BPDSI total score, the BIS-11 score and with 
BPDSI item “impulsivity” score, and with the SHI score respectively.  
On the other hand, significant differences of effect between the two drugs were found on 
measures of two core BPD symptom domains, namely affective instability and cognitive 
perceptual symptoms measured with BPDSI specific items.  More specifically, asenapine was 
found significantly superior to olanzapine in reducing the severity of affective instability.  This 
finding supports the evidence provided by Martin-Blanco and colleagues [33] of a significant 
effect of asenapine on affect dysregulation in BPD patients.   
Furthermore, we found that olanzapine was more efficacious than asenapine against cognitive- 
perceptual symptoms.  It must be acknowledged that this finding has a limited value, as our study 
was found to be underpowered to detect a difference between the drugs on the 
dissociation/paranoid ideation item of the BPDSI. However, the effect of olanzapine on this 
symptom domain in BPD patients has been widely reported in previous open-label and controlled 
studies.  Thus, Schultz and colleagues [12] demonstrated a significant reduction of psychoticism 
in BPD patients treated with olanzapine. Moreover, Zanarini and Frankenburg [19] reported a 
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significant improvement of paranoid ideation in BPD subjects treated with olanzapine versus 
placebo.  More recently, this trend was confirmed in a study involving a larger BPD sample by 
the same research group [21], which specified that the improvement in cognitive-perceptual 
symptoms (paranoid ideation and dissociation) was observed in BPD patients treated with a 
moderate dose of olanzapine, ranging from 5 to 10 mg/day.  Noteworthy, the dose used in our 
study is within this range. 
Different conclusions on this topic were drawn by Jariani and colleagues [14], who compared 
olanzapine with sertraline in BPD subjects and did not find any significant differences between 
the two medications on this type of symptoms.  However, in this study the diagnosis of BPD was 
not supported by any standardized assessment instrument, and the effects of olanzapine and 
sertraline were measured in a group of heroin-dependent patients on methadone maintenance 
therapy. 
With regard to tolerability, both treatment modalities were rather well tolerated, with only mild to 
moderate adverse effects reported in our sample. Nevertheless, some differences between 
asenapine and olanzapine were identified, with mild akathisia and restlessness/anxiety more 
commonly reported by patients receiving asenapine. Moreover, only three drop-outs among 
subjects treated with asenapine were due to adverse effects: two experienced oral hypoesthesia, 
and one moderate anxiety.  Olanzapine instead was responsible for mild somnolence and fatigue 
reported in our BPD patients.  Two patients  treated with olanzapine discontinued the drug due to 
a significant weight gain (≥ 3Kg).   
Our finding of several detectable differences in adverse effects between asenapine and olanzapine 
is overall consistent with data published in previous studies.  Typically, asenapine was associated 
with a lower incidence of weight gain than olanzapine, more common extrapyramidal symptoms 
(akathisia) and oral hypoaesthesia [36- 38, 29].  
Study limitations 
The open label design, the lack of a placebo group, and a rather small sample size constituted 
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major limitations of this trial. A further possible limitation was the exclusion of subjects with co-
occurring major depression, substance abuse or dependence in order to avoid their confounding 
effect on the outcome of the study. Given that these are common psychiatric comorbidities, the 
study sample may present clinical features that are partially different from those typically found 
in clinical practice, thereby compromising generalisability of our findings to the target 
population. Another limit is that we used the individual items of BPDSI as outcome measures of 
several BPD symptom domains, in particular of affective instability and paranoid ideation. More 
specific instruments would provide more reliable results and are needed to replicate our findings. 
A further limitation is that data on pharmacotherapies and psychotherapies received by our 
patients prior to entering the study had not been collected and compared between the two 
treatment arms.  This, however, was partially corrected by excluding patients who had received 
pharmacological and psychotherapeutic interventions in the 2 months before enrollment in the 
study. Another limitation of the study is that it was not powered to detect a difference between 
the drugs on the dissociation/paranoid ideation item of the BPDSI. It should be noticed that 
obtaining large enough samples for trials of BPD has historically proven difficult.  
We had a rather high drop-out rate in our study (21.7%), but this appears to be a common trend 
across the majority of preceding trials involving BPD patients, who are prone to poor adherence.  
However, intention to treat analysis with last observation carried forward  was performed to 
analyze data in the whole group of patients who entered the trial, and the significant effects of the 
two drugs found with the ANOVA were the same obtained in the group of completers.  
 
5. Conclusions 
In conclusion, our findings indicated that asenapine was not different from olanzapine with 
regard to overall measures of efficacy and general level of tolerability.  Effect size, eta square, 
calculated for the effect within subjects (treatment duration) ranged from 0.25 to 0.53.  These are 
high values of size effect indicating a high level of efficacy of both medications.  Moreover, 
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some differences in therapeutic effect on specific symptom clusters were identified.  Also, the 
type of adverse effects was partially different between the two drugs. The open label study 
design, lack of a placebo group, and small sample size constituted major limitations of this trial. 
Another limitation was that the study was not powered to detect a difference between the drugs 
on the dissociation/paranoid ideation item of the BPDSI. Research in this field has major clinical 
implications, contributing to identify which antipsychotic is more useful to treat specific 
symptom domains in BPD patients. Further investigations are required to replicate our findings in 
larger samples.  
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Table 1. Comparison of the baseline values of symptoms and functioning rating scales 
between the asenapine and olanzapine treated groups. 
Scale Asenapine (N=21) 
Mean ± SD 
Olanzapine (N=19) 
Mean ± SD 
ANOVA 
P 
CGI-S 4.00 ± 0.816 4.20 ± 0.789 0.584 
HAM-A 17.30 ± 4.923 18.50 ±3.951 0.555 
HAM-D 12.90 ± 3.784 15.70 ± 3.945 0.123 
BIS-11 70.40 ± 9.454 75.30 ± 12.544 0.337 
MOAS 5.50 ± 2.593 5.20 ± 3.190 0.820 
SHI 7.90 ± 5.021 4.029 ± 1.274 0.254 
SOFAS 60.10 ± 7.015 55.50 ± 9.265 0.227 
 
SD=standard deviation;  ANOVA=analysis of variance; CGI-S=Clinical Global Impression 
scale – Severity item;  HAM-A=Hamilton Anxiety Rating Scale;  HAM-D=Hamilton 
Depression Rating Scale; SOFAS=Social Occupational Functioning Assessment Scale; BIS-
11=Barrett Impulsiveness Scale – version 11; MOAS=Modified Overt Aggression Scale; 
SHI=Self Harm Inventory. 
 
 
Table 2. Comparison of baseline values of BPDSI total score and single items between the 
asenapine and olanzapine treated groups. 
Scale Asenapine (N=21) 
Mean ± SD 
Olanzapine (N=19) 
Mean ± SD 
ANOVA 
P 
BPDSI total score 55.59 ± 9.245 53.37 ± 10.961 0.630 
Abandonment 7.55 ± 1.41 7.24 ± 1.32 0.322 
Interpersonal 
relationships 
7.59 ± 0.63 7.68 ± 1.23 0.811 
Identity 4.80 ± 1.47 5.51 ± 1.22 0.203 
Impulsivity 8.31 ± 1.30 7.71 ± 1.31 0.232 
Parasuicidal behaviors 1.50 ± 1.60 1.82 ± 1.08 0.251 
Affective instability 8.21 ± 0.38 7.54 ± 1.78 0.201 
Outbursts of anger 6.91 ± 1.45 7.88 ± 1.23 0.153 
Emptiness 6.60 ± 1.85 5.82 ± 1.27 0.172 
Dissociation/paranoid 
ideation 
2.37 ± 1.58 2.49 ± 1.87 0.554 
 
SD=standard deviation; ANOVA=analysis of variance; BPDSI=borderline personality 
disorder severity index. 
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Table 3. Results of ITT-LOCF analysis for the CGI-S, HAM-A, HAM-D, and SOFAS 
scales. 
Scale Treatment Baseline 
Mean ± SD 
12 weeks 
Mean ± SD 
Within-subjects 
effect (duration) 
 
Between-
subjects effect 
(treatment)  
CGI-S Asenapine 
olanzapine 
4.00 ± 0.82 
4.20 ± 0.79 
3.70 ± 0.82 
3.90 ± 0.74 
P=0.012 
ῃ2=0.25 
P=0.561 
ῃ2=0.02 
HAM-A Asenapine 
olanzapine 
17.30 ± 4.92 
18.50 ± 3.95 
17.00 ± 4.27 
16.40 ± 4.35 
P=0.004 
ῃ2=0.3 
P=0.878 
ῃ2=0.01 
HAM-D Asenapine 
olanzapine 
12.90 ± 3.78 
15.70 ± 3.95 
12.80 ± 4.02 
15.70 ± 3.27 
P=0.862 
ῃ2=0.01 
P=0.103 
ῃ2=0.12 
SOFAS Asenapine 
olanzapine 
60.10 ± 7.06 
55.50 ± 9.27 
61.00 ± 6.58 
58.30 ± 10.06 
P=0.004 
ῃ2=0.3 
P=0.337 
ῃ2=0.03 
 
 
Table 4. Results of ANOVA repeated measures to compare the changes of the CGI-S, 
HAM-A, HAM-D,  and SOFAS scores between treatment groups. 
Scale Treatment Baseline 
Mean ± SD 
12 weeks 
Mean ± SD 
Within-subjects 
effect (duration) 
 
Between-
subjects effect 
(treatment)  
CGI-S Asenapine 
olanzapine 
4.00±0.74 
4.15±0.80 
3.75±0.75 
3.92±0.76 
P=0.013 
ῃ2=0.24 
P=0.582 
ῃ2=0.01 
HAM-A Asenapine 
olanzapine 
16.50 ± 4.83 
18.38 ± 3.91 
16.25 ± 4.25 
16.77 ± 4.26 
P=0.007 
ῃ2=0.28 
P=0.486 
ῃ2=0.02 
HAM-D Asenapine 
olanzapine 
13.17 ± 3.49 
15.31 ± 3.79 
13.08 ± 3.70 
15.54 ± 3.04 
P=0.775 
ῃ2=0.01 
P=0.110 
ῃ2=0.11 
SOFAS Asenapine 
olanzapine 
59.25 ± 6.98 
55.38 ± 8.28 
60.00 ± 6.74 
57.54 ± 9.06 
P=0.006 
ῃ2=0.29 
P=0.320 
ῃ2=0.04 
 
 
ANOVA=analysis of variance; SD=standard deviation;  CGI-S=Clinical Global Impression 
scale – Severity item; HAM-A=Hamilton Anxiety Rating Scale; HAM-D=Hamilton 
Depression Rating Scale; SOFAS=Social Occupational Functioning Assessment Scale; 
ῃ2=Eta square 
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Table 5. Results of ITT-LOCF analysis for the MOAS, BIS-11, and SHI scales. 
Scale  Treatment Baseline 
Mean ± SD 
12 weeks 
Mean ± SD 
Within-subjects 
effect 
(duration) 
 
Between-
subjects effect 
(treatment)  
MOAS asenapine 
olanzapine 
5.50 ± 2.59 
5.20 ± 3.19 
5.20 ± 2.90 
4.80 ± 3.26 
P=0.119 
ῃ2=0.1 
P=0.794 
ῃ2=0.01 
BIS-11 asenapine 
olanzapine 
70.40 ± 9.45 
75.30 ± 12.54 
64.70 ± 11.19 
72.90 ± 13.71 
P=0.005 
ῃ2=0.3 
P=0.219 
ῃ2=0.07 
SHI asenapine 
olanzapine 
7.90 ± 5.02 
10.30 ± 4.03 
6.90 ± 5.32 
8.80 ± 3.65 
P=0.004 
ῃ2=0.3 
P=0.297 
ῃ2=0.05 
 
 
 
Table 6. Results of ANOVA repeated measures to compare the changes of the MOAS, BIS-
11, and SHI scores between treatment groups. 
Scale  Treatment Baseline 
Mean ± SD 
12 weeks 
Mean ± SD 
Within-subjects 
effect 
(duration) 
 
Between-
subjects effect 
(treatment)  
MOAS asenapine 
olanzapine 
5.50 ± 2.43 
5.00 ± 3.08 
5.25 ± 2.70 
4.69 ± 3.12 
P=0.119 
ῃ2=0.1 
P=0.645 
ῃ2=0.01 
BIS-11 asenapine 
olanzapine 
71.50 ± 8.93 
75.23 ± 11.45 
66.75 ± 11.20 
73.38 ± 12.45 
P=0.005 
ῃ2=0.3 
P=0.243 
ῃ2=0.06 
SHI asenapine 
olanzapine 
8.83 ± 5.12 
11.15 ± 3.91 
8.00 ± 5.56 
10.00 ± 3.96 
P=0.005 
ῃ2=0.29 
P=0.253 
ῃ2=0.06 
 
 
ANOVA=analysis of variance; SD=standard deviation; MOAS=Modified Overt Aggression 
Scale; BIS-11=Barrett Impulsiveness Scale – version 11; SHI=Self Harm Inventory; ῃ2=Eta 
square 
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Table 7. Results of ITT-LOCF analysis for the BPDSI total score and single items. 
Scale  Treatment Baseline 
Mean ± SD 
12 weeks 
Mean ± SD 
Within-
subjects effect 
(duration) 
 
Between-
subjects effect 
(treatment)  
BPDSI total score asenapine 
olanzapine 
55.59 ± 9.25 
53.37 ± 
10.96 
51.35 ± 9.33 
49.12 ± 
11.73 
P=0.001 
ῃ2=0.53 
P=0.634 
ῃ2=0.01 
Abandonment  asenapine 
olanzapine 
7.55 ± 1.41 
7.24 ± 1.32 
7.09 ± 1.32 
6.69 ± 1.12 
P=0.001 
ῃ2=0.53 
P=0.732 
ῃ2=0.01 
Interpersonal 
relationships 
asenapine 
olanzapine 
7.59 ± 0.63 
7.68 ± 1.23 
6.89 ± 1.32 
7.29 ± 1.40 
P=0.001 
ῃ2=0.53 
P=0.565 
ῃ2=0.02 
Identity disturbance asenapine 
olanzapine 
4.80 ± 1.47 
5.51 ± 1.22 
4.72 ± 1.61 
5.40 ± 1.29 
P=0.541 
ῃ2=0.02 
P=0.256 
ῃ2=0.06 
Impulsivity  asenapine 
olanzapine 
8.31 ± 1.30 
7.71 ± 1.31 
7.78 ± 1.36 
7.00 ± 1.58 
P=0.001 
ῃ2=0.53 
P=0.301 
ῃ2=0.04 
Parasuicidal 
behaviors 
asenapine 
olanzapine 
1.50 ± 1.60 
1.82 ± 1.08 
1.46 ± 1.52 
1.67 ± 1.33 
P=0.092 
ῃ2=0.14 
P=0.682 
ῃ2=0.01 
Affective instability asenapine 
olanzapine 
8.21 ± 0.38 
7.54 ± 1.78 
4.58 ± 1.1 
6.86 ± 1.67 
P=0.001 
ῃ2=0.53 
P=0.001 
ῃ2=0.53 
Outbursts of anger asenapine 
olanzapine 
6.91 ± 1.45 
7.88 ± 1.23 
6.05 ± 1.15 
7.19 ± 1.82 
P=0.001 
ῃ2=0.53 
P=0.312 
ῃ2=0.04 
Emptiness  asenapine 
olanzapine 
6.60 ± 1.85 
5.82 ± 1.27 
5.81 ± 1.58 
5.27 ± 1.11 
P=0.001 
ῃ2=0.53 
P=0.630 
ῃ2=0.01 
Dissociation/paranoid 
ideation 
asenapine 
olanzapine 
2.37 ± 1.58 
2.49 ± 1.87 
2.36 ± 1.15 
1.67 ± 1.83 
P=0.001 
ῃ2=0.53 
P=0.021 
ῃ2=0.21 
 
ANOVA=analysis of variance; SD=standard deviation; BPDSI=borderline personality 
disorder severity index; ῃ2=Eta square 
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Table 8. Results of ANOVA repeated measures to compare the BPDSI total score and single 
items between treatment groups. 
Scale  Treatment Baseline 
Mean ± SD 
12 weeks 
Mean ± SD 
Within-
subjects effect 
(duration) 
 
Between-
subjects effect 
(treatment)  
BPDSI total score asenapine 
olanzapine 
55.05 ± 8.50 
52.65 ± 9.95 
51.52 ± 8.50 
49.38 ± 
10.51 
P=0.001 
ῃ2=0.53 
P=0.548 
ῃ2=0.02 
Abandonment  asenapine 
olanzapine 
7.59 ± 1.45 
7.27 ± 1.38 
7.06 ± 1.34 
6.67 ± 1.21 
P=0.001 
ῃ2=0.53 
P=0.682 
ῃ2=0.01 
Interpersonal 
relationships 
asenapine 
olanzapine 
7.63 ± 0.82 
7.70 ± 1.42 
6.84 ± 1.28 
7.31 ± 1.30 
P=0.001 
ῃ2=0.53 
P=0.672 
ῃ2=0.01 
Identity disturbance asenapine 
olanzapine 
4.81 ± 1.65 
5.53 ± 1.18 
4.62 ± 1.72 
5.31 ± 1.43 
P=0.437 
ῃ2=0.02 
P=0.186 
ῃ2=0.07 
Impulsivity  asenapine 
olanzapine 
8.36 ± 1.51 
7.71 ± 1.45 
7.78 ± 1.39 
6.96 ± 1.47 
P=0.001 
ῃ2=0.53 
P=0.230 
ῃ2=0.06 
Parasuicidal 
behaviors 
asenapine 
olanzapine 
1.52 ± 1.70 
1.80 ± 1.12 
1.45 ± 1.73 
1.67 ± 1.31 
P=0.086 
ῃ2=0.14 
P=0.631 
ῃ2=0.01 
Affective instability asenapine 
olanzapine 
8.27 ± 0.47 
7.55 ± 1.68 
4.54 ± 1.52 
6.85 ± 1.47 
P=0.001 
ῃ2=0.53 
P=0.001 
ῃ2=0.53 
Outbursts of anger asenapine 
olanzapine 
6.94 ± 1.56 
7.84 ± 1.51 
6.02 ± 1.27 
7.17 ± 1.71 
P=0.001 
ῃ2=0.53 
P=0.295 
ῃ2=0.05 
Emptiness  asenapine 
olanzapine 
6.65 ± 1.96 
5.83 ± 1.22 
5.80 ± 1.85 
5.23 ± 1.32 
P=0.001 
ῃ2=0.53 
P=0.525 
ῃ2=0.03 
Dissociation/paranoid 
ideation 
asenapine 
olanzapine 
2.38 ± 1.75 
2.51 ± 1.99 
2.35 ± 1.32 
1.61 ± 1.62 
P=0.001 
ῃ2=0.53 
P=0.012 
ῃ2=0.25 
 
ANOVA=analysis of variance; SD=standard deviation; BPDSI=borderline personality 
disorder severity index; ῃ2=Eta square 
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